812690-40-7 Usage
Uses
Used in Pharmaceutical Industry:
1-BOC-4-CYCLOPENTYLAMINO-PIPERIDINE is used as a reactant in the synthesis of aminopiperidines, which are known as iNOS inhibitors. These inhibitors play a crucial role in regulating the production of nitric oxide in the body, which can have therapeutic applications in treating various inflammatory and cardiovascular conditions.
In the synthesis process, the Boc protecting group is first removed to generate the free amine, which can then be further functionalized or used in the formation of more complex molecules. The cyclopentyl and piperidine moieties in 1-BOC-4-CYCLOPENTYLAMINO-PIPERIDINE provide unique structural features that can be exploited to design and develop novel therapeutic agents with improved pharmacological properties.
Overall, 1-BOC-4-CYCLOPENTYLAMINO-PIPERIDINE is a valuable compound in the field of medicinal chemistry, with potential applications in the development of new drugs and therapeutic agents targeting various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 812690-40-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,2,6,9 and 0 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 812690-40:
(8*8)+(7*1)+(6*2)+(5*6)+(4*9)+(3*0)+(2*4)+(1*0)=157
157 % 10 = 7
So 812690-40-7 is a valid CAS Registry Number.
812690-40-7Relevant academic research and scientific papers
LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS
-
Page/Page column 23, (2011/10/10)
The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, n, R1, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Discovery of a series of aminopiperidines as novel iNOS inhibitors
Bourdonnec, Bertrand Le,Leister, Lara K.,Ajello, Christopher A.,Cassel, Joel A.,Seida, Pamela R.,O'Hare, Heather,Gu, Minghua,Chu, Guo-Hua,Tuthill, Paul A.,DeHaven, Robert N.,Dolle, Roland E.
, p. 336 - 343 (2008/09/18)
Nitric oxide (NO), a mediator of various physiological and pathophysiological processes, is synthesized by three isozymes of nitric oxide synthase (NOS). Potential candidate clinical drugs should be devoid of inhibitory activity against endothelial NOS (eNOS), since eNOS plays an important role in maintaining normal blood pressure and flow. A new series of aminopiperidines as potent inhibitors of iNOS were identified from a HTS lead. From this study, we identified compound 33 as a potent iNOS inhibitor, with >25-fold selectivity over eNOS and 16-fold selectivity over nNOS.
